Doudna most deserving of CRISPR-Cas9 patent, says poll

With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll
CRISPR Patent Pollasking who deserves the patent for use of CRISPR-Cas9 as a tool.

Feng Zhang got only just over half the votes of Doudna.

Another take home message from this poll is that a sizable minority–almost one in five– said neither should have a patent on this technology.

Geographically the results were fairly consistent across countries, but notably in the UK the top response was, “Neither”.

This poll is of course non-scientific, but it is interesting even so to see a fairly decisive result.

Let’s see ultimately what happens with the US Patent Office.

Who deserves the patent on using CRISPR-Cas9 in human cells? Take our poll

There is no hotter technology than CRISPR-Cas9 gene editing tools.

Perhaps it is not surprising then that there is a patent dispute over it, which falls into two camps:

(1) Jennifer Doudna & Emmanuelle Charpentier, and (2) Feng Zhang.

Who deserves the intellectual property for use of CRISPR-Cas9 in human cells?

Take our poll.